Pharming Group NV (PHAR) - Total Liabilities
Based on the latest financial reports, Pharming Group NV (PHAR) has total liabilities worth $220.41 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Pharming Group NV long-term investment allocation to see how much of total assets are deployed in long-term investments.
Pharming Group NV - Total Liabilities Trend (2005–2025)
This chart illustrates how Pharming Group NV's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Pharming Group NV balance sheet assets.
Pharming Group NV Competitors by Total Liabilities
The table below lists competitors of Pharming Group NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OCI NV
AS:OCI
|
Netherlands | €1.67 Billion |
|
Kossan Rubber Industries Bhd
KLSE:7153
|
Malaysia | RM352.84 Million |
|
Jiangsu Maixinlin Aviation Science & Technology Corp. A
SHG:688685
|
China | CN¥2.11 Billion |
|
DCB Bank Limited
NSE:DCBBANK
|
India | Rs-65.35 Billion |
|
Dometic Group AB (publ)
ST:DOM
|
Sweden | Skr25.73 Billion |
|
Resurs Holding AB
ST:RESURS
|
Sweden | Skr42.62 Billion |
|
Chongqing Gangjiu Co Ltd
SHG:600279
|
China | CN¥5.14 Billion |
|
Osisko Development Corp
V:ODV
|
Canada | CA$516.31 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Pharming Group NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PHAR equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharming Group NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharming Group NV (2005–2025)
The table below shows the annual total liabilities of Pharming Group NV from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $222.79 Million | +24.52% |
| 2024-12-31 | $178.92 Million | -26.69% |
| 2023-12-31 | $244.07 Million | +10.36% |
| 2022-12-31 | $221.16 Million | +8.20% |
| 2021-12-31 | $204.40 Million | +6.24% |
| 2020-12-31 | $192.39 Million | +38.88% |
| 2019-12-31 | $138.53 Million | -20.76% |
| 2018-12-31 | $174.81 Million | -1.14% |
| 2017-12-31 | $176.82 Million | +69.29% |
| 2016-12-31 | $104.45 Million | +182.34% |
| 2015-12-31 | $37.00 Million | +17.58% |
| 2014-12-31 | $31.46 Million | -13.68% |
| 2013-12-31 | $36.45 Million | +12.52% |
| 2012-12-31 | $32.40 Million | -3.43% |
| 2011-12-31 | $33.55 Million | -7.23% |
| 2010-12-31 | $36.16 Million | -40.72% |
| 2009-12-31 | $60.99 Million | -19.70% |
| 2008-12-31 | $75.96 Million | -34.60% |
| 2007-12-31 | $116.14 Million | +200.99% |
| 2006-12-31 | $38.59 Million | +457.08% |
| 2005-12-31 | $6.93 Million | -- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more